• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ipsen S.A. ADR (OP: IPSEY )

    29.84 -0.97 (-3.14%)
    Streaming Delayed Price Updated: 2:30 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 714
    Open 29.27
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 30.81
    Today's Range 29.27 - 29.84
    52wk Range 26.97 - 34.34
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
    In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. 
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
    The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -0.33%
    -0.33%
    1 Month
    +7.00%
    +7.00%
    3 Month
    -10.30%
    -10.30%
    6 Month
    +4.83%
    +4.83%
    1 Year
    -6.26%
    -6.26%

    More News

    Read More
    Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    3 Promising Biotech Stocks Flying Under the Radar
    Via InvestorPlace
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
    From Virtual Investor Conferences
    Via GlobeNewswire
    Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
    Via Benzinga
    Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
    Via Benzinga
    Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
    Via Benzinga
    What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
    Via Benzinga
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
    From Virtual Investor Conferences
    Via GlobeNewswire
    Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
    From Ipsen
    Via Business Wire
    Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
    From Ipsen
    Via Business Wire
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
    From Virtual Investor Conferences
    Via GlobeNewswire
    Why These Two Biotech Stocks Blasted Higher This Week
    Via The Motley Fool
    2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
    Via The Motley Fool
    France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
    Via Benzinga
    Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
    From Ipsen
    Via Business Wire
    Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
    From Ipsen
    Via Business Wire
    Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
    Via Benzinga
    Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
    From Ipsen
    Via Business Wire
    Why Merrimack Shares Are Surging Over 200% Today?
    Via Benzinga
    Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
    From Ipsen
    Via Business Wire
    Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
    Via Benzinga
    Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
    From Ipsen
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.